Healthcare, being intrinsic to human existence, cannot be perceived in isolation with the technological advancements benefitting the globe. Artificial Intelligence (AI), the most perceptible technological advancement, is finding increasing inroads in medicine technology (MedTech). In its simplest terms, MedTech, also known as health technology, is the application of organized knowledge to develop procedures and systems aimed at addressing health concerns. If the report of India Brand Equity Foundation (IBEF), Ministry of Commerce, is relied on, Indian MedTech market is expected to reach US $50 billion by 2025. With such exponential rise in MedTech, comes the inevitable need to regulate its cardinal foundation – medical data. The Indian legal canvass concerning regulation of medical data lacks clarity and has sufficient traces of ambiguity that might surface post the enactment of Data Protection Bill, 2021.
Please click here to read the full article by Gaurav G Arora, published in ET Insights.
Gaurav G. Arora is a Partner at JSA with over 12 years of experience advising multinational corporations, investment funds, and high-growth businesses on mergers & acquisitions, private equity investments, corporate structuring, cross-border transactions, foreign direct investment, and general corporate matters. He regularly advises clients on complex domestic and international transactions across the technology, healthcare, manufacturing, real estate, retail, and services sectors. Gaurav is recognised as an ALB India Rising Star and among the Top 10 Young Lawyers by ALB Thomson Reuters.